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Prostaglandin E2 production and metabolism in human breast cancer cells
and breast fibroblasts. Regulation by inflammatory mediators
MP Schrey and KV Patel
Unit ofMetabolic Medicine, St Mary's Hospital Medical School, Imperial College ofScience, Technology and Medicine, London
W2 IPG, UK.
Summary Malignant human breast tumours contain high levels of prostaglandin E2 (PGE2). However, the
mechanisms controlling PGE2 production in breast cancer are unknown. This in vitro study investigates the
capacity for PGE2 synthesis and metabolism in several human breast cancer cell lines and early passage human
breast fibroblasts and seeks to identify potential regulatory factors which may control these pathways. Basal
PGE2 production rose up to 30-fold in breast fibroblast lines on addition of exogenous arachidonic acid
(10OM), whereas no such changes were observed in six out of seven cancer cell lines, with the exception of
modest increases in MDA-MB-231 cells. Interleukin lp (IL-1p) also induced PGE2 production in breast
fibroblasts in the presence of excess substrate, consistent with cyclo-oxygenase induction by the cytokine.
Under these conditions only Hs578T cells and MDA-MB-231 cells demonstrated large increases in PGE2 in
response to IL-1p or phorbol ester; no such responses were seen in MCF-7, T47-D, ZR-75-1, BT-20 or
CLF-90-1 cells. In the absence of added arachidonate, bradykinin (BK) and endothelin-I (ET-1), potentiated
PGE2 production in IL-lp-treated fibroblasts, possibly by mobilising endogenous substrate. PGE2 also
stimulated ET-1 production by breast cancer cells. In co-cultures with T47-D cells both basal and stimulated
PGE2 production by breast fibroblasts was greatly reduced. This appeared to be due to metabolic inactivation
by the cancer cell since T47-D cells readily converted PGE2 to 15-keto-PGE2. This apparent 15-hydroxy-PG
dehydrogenase activity was stimulated by TPA and inhibited by cycloheximide. In conclusion, breast fibro-
blasts, particularly under the influence of inflammatory mediators, provide a potentially rich source for PGE2
production in breast tumours, whereas significant contributions from the epithelial tumour component may be
restricted to cancer cells exhibiting an invasive phenotype. Metabolic inactivation by the cancer cells may also
play an important role in the regulation of breast tumour PGE2 levels.
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Elevated levels of prostaglandin E2 (PGE2) have been widely
reported in malignant human breast tumours (Bennett, 1979;
Rolland et al., 1980; Karmali et al., 1983) as well as experi-
mental murine mammary tumour models (Tan et al., 1974).
Furthermore, these high levels are often associated with
tumours exhibiting high metastatic potential (Rolland et al.,
1980; Karmali et al., 1983). Similarly, in vitro studies with
tissue explants or primary cultures of human breast tumour
cells have also demonstrated increases in PGE2 production
from malignant tissue compared with benign or normal
(Watson and Chuah, 1985; 1992). Although the patho-
physiological significance of this correlation in the context of
a role for PGE2 in breast cancer growth and progression is
unclear, several studies with murine mammary tumour
models indicate that PGE2 may indeed play a multifunctional
role in controlling growth, metastasis and host immune res-
ponses (Foecking et al., 1982; Fulton and Heppner 1985;
Fulton et al., 1991). PGE2 has been shown to be mitogenic
for normal human and murine mammary epithelial cells
(Bandyopadhyay et al., 1987; Balakrishnan et al., 1989) but
inhibits both human breast cancer cell growth (Fentiman et
al., 1984) and DNA synthesis in human breast fibroblasts
(Patel and Schrey, 1992). Both stromal (Fernig et al., 1990)
and epithelial (Bandyopadhyay et al., 1987) murine mam-
mary cells have been implicated as potential sources for this
eicosanoid.
Notwithstanding the considerable evidence supporting a
role for PGE2 production in breast tumour biology, neither
the nature of the cell types involved nor the paracrine factors
controlling PGE2 levels in human breast tumour tissue are
known. In the present study we sought to address these
questions by monitoring PGE2 production in several human
breast cancer cell lines and breast stromal fibroblasts in
response to various putative agonists of both phospholipase
A2 and cyclo-oxygenase, the two rate-limiting enzymes in PG
synthesis.
Under the combined influence of the inflammatory media-
tors IL-li and BK breast fibroblasts represent a potentially
rich source of PGE2. In contrast, under the various condi-
tions employed we were unable to detect any PGE2 produc-
tion in the majority of breast cancer cell lines investigated,
with the exception of two hormone-independent lines (MDA-
MB-231 and Hs578T). Net PGE2 production by breast fibro-
blasts was greatly reduced in co-cultures with breast cancer
cells (T47-D or MCF-7). This appeared to be due to meta-
bolic inactivation by PG dehydrogenase present in the cancer
cells.
Materials and methods
[5,6,8,11,12,14,15(n)-3H] PGE2 160 Ci mmol-' was obtained
from Amersham International UK. Anti-PGE2 methyl oxime
was a gift from Dr RW Kelly, Edinburgh, UK. Antibodies to
endothelin 1 (ET-1) were obtained from Alan O'Shea and
Terry Jowett, University College London, UK. 15-Keto
PGE2 was obtained from Cascade Biochem, Reading, UK.
Arachidonate and all other PG metabolites as well as
bradykinin (BK), des-Arg9BK, ET-1 and 12-0-
tetradecanoylphorbol (TPA) were purchased from Sigma
(UK). IL-lp was obtained from Bachem (UK). All culture
media and cell culutre products were obtained from Flow
Laboratories (UK). All other chemicals and reagents were of
analytical grade and were obtained from Fison (UK).
Human breast cancer cell lines
T47-D, MDA-MD-231 and Hs578T cell lines were obtained
from the National Cell Bank at Porton Down, UK. MCF-7,
ZR-75-1 and BT-20 cells were respectively obtained from Dr
M Lippman (Georgetown University, Washington DC,
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USA), Dr M O'Hare (Haddow Laboratories, Sutton, UK)
and Dr J Taylor-Papadimitriou (Imperial Cancer Research
Fund Laboratories, London, UK). CLF-90-1 cells were
established in our own laboratory from tissue fragments of a
primary ductal infiltrating carcinoma of the breast and dis-
play a typical epithelial morphology in culture. CLF-90-1
cells are oestrogen and progesterone receptor-positive and
exhibit growth stimulation and growth inhibition in response
to oestradiol and medroxyprogesterone acetate respectively.
All these cell lines were maintained as previously described
(Patel and Schrey, 1990) in Eagle's minimal essential medium
(EMEM) supplemented with glutamine (2 mM) and bicarbon-
ate (4.5 mM) containing 20 mM Hepes (pH 7.4) and 5% fetal
calf serum (FCS) with the exception of BT-20 which was
grown in 10% FCS.
Human breastfibroblasts
Human breast fibroblasts (HBFs) were prepared and main-
tained in culture as previously described (Patel and Schrey,
1992). Normal tissue was obtained from three women under-
going reductive mammoplasty. Following tissue disaggrega-
tion with collagenase, primary cultures grown to confluence
were subcultured in EMEM containing the above supple-
ments with 10% FCS. The three cell lines obtained (HBF-
l0,-11,-12) exhibited typical fibroblast-like morphology at
confluence forming whorls and parallel bundles of spindle-
shaped cells. Cells with epithelial morphology were absent.
Experiments with these breast fibroblast cultures employed
cells between passages 3 and 7.
For studies monitoring PGE2 production in either fibro-
blasts or cancer cell lines, cells were grown to 70%
confluence in either 12- or 24-well plates (containing 1 ml or
0.5 ml medium respectively), serum-starved for 4 h, and
incubated for 18 h in the presence or absence of IL-1p and/or
arachidonic acid. The next day the cells were incubated in
fresh media for various times with different agents (see
Figure legends for details). Unless otherwise stated studies
employing cancer cell lines monitored PGE2 production dur-
ing the initial 18 h period. PGE2 release into the medium was
measured by radioimmunoassay (see below).
Co-culture studies
In some experiments comparative studies were conducted to
monitor PGE2 production in co-cultures of breast fibroblasts
and T47-D cells and separate parallel cultures of fibroblasts
and T47-D cells alone. Fibroblasts grown to 50% confluence
in 12-well plates with EMEM containing 10% FCS were
seeded with T47-D cells (5 x 105 cells) and cultured for 18 h.
Separate cultures comprising appropriate numbers of either
T47-D cells or fibroblasts alone were also established. All
cultures were serum-starved for 4 h and incubated for a
further 18 h in the presence or absence of IL-ip (1 ng ml-')
in EMEM containing 10 LM arachidonate. Instead of being
selected for co-culture some fibroblasts were incubated with
T47-D cell-conditioned medium throughout this protocol.
This conditioned medium was obtained from T47-D cells
incubated overnight under exactly the same conditions of
cancer cell density and media composition employed in the
co-culture study. PGE2 release into the media after this 18 h
incubation was measured by radioimmunoassay. PGE2 was
undetectable in T47-D cell conditioned medium.
In studies employing breast cancer cell lines, cell numbers
were determined by releasing and counting cell nuclei in a
Coulter counter as previously described (Patel and Schrey,
1990). This technique was readily applicable to co-culture
studies since fibroblasts remained attached and resistant to
the Zaponin (Coulter Electronic, Luton, UK) treatment con-
ditions employed to release cancer cell nuclei. Fibroblast
content per well was quantitated by measuring cellular pro-
tein using the method of Lowry et al. (1951). However, no
differential measurements of either cancer cell number or
fibroblast content were apparent in any incubations over the
relatively short time span of the experiments irrespective of
the different conditions employed. Hence, PGE2 production
has been consistently expressed as ng ml' incubation
medium.
PGE2 measurement radioimmunoassay
All experiments monitoring PGE2 production by fibroblasts
and cancer cell lines were performed in serum-free EMEM.
Release of PGE2 into the culture media was measured using
a specific radioimmunoassay as previously described (Kelly et
al., 1986). The antisera employed was raised to the methyl
oxime of PGE2. At the end of each experiment aliquots of
the culture media were derivatised at room temperature over-
night with equal volumes of methyloximating reagent (Kelly
et al., 1986). No agents employed in this study interfered
with the assay at the concentrations used. The sensitivity of
the assay is 15 pg ml- '. The percentage cross-reactivity of the
antibody with various derivatised arachidonate metabolites
has been determined as: PGE2 100; 15-keto PGE2 0.25;
PGF2. <0.02; PGB2 0.2; PGD2 0.02; TXB2 <0.02; 6-keto
PGFIc, 0.02. The mean intra-assay coefficient of variation was
6.2%. All samples within the same experimental group were
measured in the same assay.
Endothelin immunoradiometric assay
The production of ET-1 by MCF-7 cells was measured using
a specific solid phase-based sandwich assay in 96-well micro-
titre plates as previously described (Patel and Schrey, 1995).
The sensitivity of the assay is 0.5pmoll1' with percentage
cross-reactivities for ET-1, big ET-1, ET-2 and ET-3 being
100, 0.01, 100 and 50 respectively.
[3H]PGE2 metabolism
T47-D cells grown to 70% confluence in 12-well plates were
serum starved for 4 h and then incubated for 24 h in 1 ml
medium with or without TPA (10 nM) or cycloheximide
(1 LM). During the last 4 h of this 24 h period [3H]PGE2
(0.1I Ci) was added to the cells at a final concentration of
1 tLM. Incubations were terminated and PGE2 metabolites
were extracted, chromatographed and the radioactivity
profile determined. The position of various PGE2 metabolites
including 15-keto-PGE2 was determined with various stan-
dards and RF values obtained agreed with those previously
reported for this TLC system (Mitchell et al., 1993). Control
parallel incubations were always performed with [3H]PGE2 in
the absence of cells and the corresponding blanks for each
area of the plate were subtracted from the appropriate prod-
uct bands.
Expression ofdata
All values are presented as the means ± s.d. from individual
representative experiments each performed in triplicate unless
otherwise stated. Statistical evaluation of the data when com-
paring control groups with treatment groups was by the
Student's t-test.
Results
PGE2production in different human mammary cell lines
PGE2 production was monitored in ten different human
breast mammary cell lines: three stromal fibroblast lines
(HBF-10,-11,-12); four hormone-dependent cancer cell lines
(MCF-7, T47-D, ZR-75-1 and CLF-90-1) and three
hormone-independent lines (BT-20, MDA-MB-231 and
Hs578T). Under optimal conditions in the presence of 10 fM
arachidonate, basal PGE2 production increased up to 30-fold
in breast fibroblasts, whereas with the exception of MDA-
MB-231 cells, no changes in PGE2 production were observed
in the presence of exogenous substrate in any breast cancer
cell lines (Table I). IL-il, appeared to be a potent inducer of
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Table I PGE2 production in different human mammary cell lines
PGE2production, pgml-'
Cell line Basal AA IL-1p IL-1p+AA TPA + AA
HBF-10 45 13a 1380 182* 344 20* 3441 132** NDb
HBF-l1 22 4 358 14* 485 63* 2760 208** ND
HBF-12 23±9 763±42* 674 100* 4515 510 ND
MCF-7, T47-D, <15 <15 <15 <15 <15
ZR-75-1, BT-20, <15 <15 <15 <15 <15
CLF-90-1 <15 <15 <15 <15 <15
MDA-MB-231 31 13 162 20* 22 2 236 12* 966± 204*
Hs578T 25 8 44 2 27 4 610 114* 4410± 531*
PGE2 production by fibroblasts (HBF 10-12) and cancer cell lines was measured by
radioimmunoassay following treatment of the cells with or without arachidonic acid (AA,
10ZtM), IL-lIp (1 ngml1) or TPA (10 nM) as described in Materials and methods,
aMean ± s.d., n = 3. bND, not determined. *P<0.001 compared withbasal; **P<0.001 for
synergistic response.
cyclo-oxygenase in both breast fibroblasts and the carcino-
sarcoma line Hs578T, since synergism was clearly observed
with IL-lp in the presence of arachidonate (Table I). No
cytokine-inducible PGE2 production was detectable in any
other breast cancer cell lines. The phorbol ester TPA, a
known inducer of cyclo-oxygenase in various epithelial cell
lines, caused large increases in PGE2 in MDA-MB-231 and
Hs578T cells but was without effect in any other breast
cancer cell line (Table I). In a separate study TPA also
enhanced PGE2 production in breast fibroblasts in the
presence of arachidonate, the respective values for
arachidonate alone, TPA alone and arachidonate plus TPA
being: 357 ± 33, 58 + 7 and 3799 ± 604 pg ml-' (mean ± s.d.,
n = 3). Cell lines unresponsive to IL-l or TPA (e.g. MCF-7,
T47-D) with regard to PGE2 production exhibited evidence
of functional receptors for these agonists as demonstrated by
increases in ET-1 production in response to both agonists
(MP Schrey and KV Patel, unpublished results). Cyclic AMP
(cAMP) elevation is essential for IL-lp-stimulated PGE2 pro-
duction in certain cell types (Burch and Connor, 1992). How-
ever, PGE2 production by either MCF-7 cells or T47-D cells
remained unresponsive to IL-lp in the presence of cAMP
elevating agonists such as cholera toxin or forskolin. PGE2
synthesis was also undetectable in MCF-7 and T47-D cells
incubated with either oestradiol or epidermal growth factor
(MP Schrey and KV Patel, unpublished results). Transient
pretreatment of breast fibroblasts with indomethacin reduced
basal PGE2 production in the presence of 10tLM arachidonate
but did not prevent subsequent induction of PGE2 produc-
tion by IL-lp (Figure 1). Previous studies in various cell
types including fibroblasts have shown IL-lp induction of
cyclo-oxygenase 2 (COX-2) activity and PGE2 production to
be inhibited by glucocorticoids (Raz et al., 1990; Crofford et
al., 1994). In the present study, dexamethasone treatment
also inhibited IL-ll-induced PGE2 production in breast
fibroblasts (Figure 1).
Synergistic interactions between IL-1p and inflammatory
peptides during.fibroblast PGE2production
In the absence of exogenous arachidonate, optimal IL-ill-
induced PGE2 production in breast fibroblasts was greatly
enhanced in the presence of BK (Figure 2a). Similarly, syner-
gism in IL-ip pretreated fibroblasts was also observed in
response to the B, BK-receptor agonist des-Arg9-BK or ET-1
(Figure 2b). Apparent cyclo-oxygenase activity as measured
by PGE2 production in the presence of 10 iM arachidonate
was unaffected by BK, des-Arg9-BK or ET-1, whereas PGE2
synthesis in IL-lp-treated fibroblasts was enhanced 5.7-fold
in the presence of exogenous substrate (Figure 2b).
Apparent inhibition ofPGE2production in stromal/epithelial
co-cultures
In view of the heterogenous nature of primary cell or tissue
cultures previously employed to monitor PGE2 production in
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Figure 1 Effect of dexamethasone and indomethacin pretreat-
ment on IL-lp-stimulated PGE2 production in breast fibroblasts.
HBF-10 cells were pretreated for 30 min with or without
indomethacin, (Indo; 10 lAM), washed twice and incubated for
18h in medium containing arachidonic acid (IOIM) in the
absence ([=]) or presence ( 1) of IL-IB (Ingml-') and/or
dexamethasone (Dex; I JiM). PGE2 production was then
measured. All values represent means ± s.d., n = 3. *P<0.01 for
stimulation compared with appropriate untreated and
indomethacin-pretreated controls; **P<0.001 for inhibition of
IL-lp responses by dexamethasone. tP<0.01 for inhibition com-
pared with untreated controls.
human breast tumours, we have also examined the effect of
stromal/epithelial co-cultures on PGE2 production. The effect
of overnight co-culture with T47-D cells on basal and IL-ill-
stimulated PGE2 production by fibroblasts is shown in
Figure 3a. PGE2 production in T47-D cells alone is undetect-
able (compare Table I), whereas basal and IL-lp-stimulated
production by breast fibroblasts was inhibited by 83% and
42% respectively when co-cultured with T47-D cells (Figure
3a). The lack of effect of T47-D cell-conditioned medium on
fibroblast PGE2 production compared with that observed in
co-cultures is shown in Figure 3b. An inhibitory effect of
T47-D cells per se on both basal and IL-lll-stimulated PGE2
production in fibroblasts is clearly evident (Figure 3b). Basal
fibroblast PGE2 production was similarly inhibited in co-
cultures with T47-D cells or MCF-7 cells (Figure 3c). To
*
*
**investigate a potential metabolic capacity of breast cancer
cells to modulate net PGE2 production in co-culture, the
recovery of exogenous PGE2 added to T47-D cells was moni-
tored. A temporal decline in exogenous PGE2 recovered from
T47-D cell cultures was observed (Figure 3 insert). This
decreased recovery of exogenous PGE2 appeared to be due to
the T47-D cells themselves rather than soluble factors elabor-
ated by the cells as evidenced by differential PGE2 recovery
in the presence or absence of T47-D cells vs T47-D cell-
conditioned medium (Figure 3d).
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PGE2 metabolism by T47-D cells
To further investigate the metabolic fate of PGE2 in the
presence of breast cancer cells, T47-D cells were incubated
with [3H]PGE2. Following extraction and TLC the major
metabolite co-eluted with 15-keto PGE2, with no conversion
to PGF2, being detectable (Figure 4a). These data indicate
that the predominant metabolic pathway for PGE2 in T47-D
cells involves the enzyme 15-hydroxy PG dehydrogenase. In
similar parallel studies with MDA-MB-231 cells or human
breast fibroblasts we were unable to detect significant meta-
bolism of PGE2 (MP Schrey and KV Patel, unpublished
observations). Recent studies in human promyelocytic leu-
kaemia (HL-60) cells report a rapid turnover of this PG
dehydrogenase, continued enzyme synthesis being necessary
to maintain activity (Xun et al., 1991). Furthermore, de novo
enzyme synthesis and activity was stimulated in these cells by
protein kinase C (PKC)-activating phorbol esters (Xun et al.,
1991). In the present study, when T47-D cells were pretreated
with TPA or cycloheximide, basal metabolic conversion of
PGE2 to 15-keto PGE2 + PGE metabolite (PGEM) was in-
creased by 77% or inhibited by 93% respectively (Figure 4b).
PGE2 stimulates ET-J production in breast cancer cells
Several human breast cancer cell lines including MCF-7 pro-
duce ET-1 which may exercise a paracrine mitogenic
influence on neighbouring breast stroma (Schrey et al.,
1992a). Another novel paracrine action of ET-1 is the
stimulation of PGE2 production by breast fibroblasts as des-
cribed above (see Figure 2b). To investigate the potential for
a bidirectional paracrine cross-talk between epithelial and
stromal cells, the effect of PGE2 on ET-1 production by
MCF-7 cells was also assessed. During a 24 h incubation,
basal ET-1 production by MCF-7 cells was increased from
30.1 ± 0.3 to 70.9 ± 6.9 fmol 10-6 cells (P<0.001) in the
presence of PGE2 (1 SAM).
b
2.5 -
2.0-
E
c 1.5-
CL
1.0-
0.5-
0.0 -
E AA
E IL-1
**
**
**
AA
Figure 2 Effect of IL-Ip pretreatment on breast fibroblast PGE2
production in response to BK, des-Arg9BK, ET-1 and arachi-
donic acid, AA. (a) Fibroblasts (HBF-12) were pretreated with
different concentrations of IL-1p for 18 h and PGE2 production
was measured in a subsequent 4 h incubation in the absence (@)
or presence of BK, 0.01 tLM (0) and 1 gAM (A). (b) Fibroblasts
(HBF-10) were similarily pretreated with ( ) or without
(LII) IL-Ip ( ng ml-L') before incubation in the presence or
absence of BK (1I M), des-Arg9BK (1jAM) and/or AA (10 1AM)
( ). Some fibroblasts were pretreated with IL-1Ip and then
incubated with AA alone ( _). All values represent means
± s.d., n = 3. *P<0.01 for stimulation compared with basal
control values. **P<0.001 for potentiation of responses in the
presence of IL-1pI.
Discussion
Several studies have reported elevated levels of PGE2 in
malignant human breast tumour tissue (Bennett, 1979; Rol-
land et al., 1980; Karmali et al., 1983; Watson and Chuah,
1985, 1992). However, the cell types involved and the
regulatory mechanisms controlling PGE2 levels in breast
tumours are unknown. A major limitation of in vitro studies
employing breast tumour tissue or even primary cell cultures
derived from tumour tissue is the presence of non-malignant
cells which may obscure the true capacity of PG synthesis by
the cancer cells. Indeed, the stromal fibroblast component
may represent a significant contribution to tumour cell mass
given the marked desmoplasia often associated with breast
cancer. The availability of established human breast cancer
cell lines and early passage human breast fibroblasts provide
simplified experimental models which permit the study of PG
production under various culture conditions.
Two important criteria essential for the control of optimal
PGE2 production are the regulation of substrate availability
and the capacity to metabolise free arachidonate to PGE2.
Furthermore, phospholipase A2 and cyclo-oxygenase, the two
rate-limiting enzymes involved, are themselves subject to
regulation by a variety of paracrine factors. In this respect it
is desirable to know if the activity of these enzymes is
constitutively expressed in breast cancer cells and fibroblasts
and whether a potential exists for their induction and/or
activation.
In the present study apparent constitutive cyclo-oxygenase
activity, as measured by PGE2 production in the presence of
exogenous substrate was only detectable in one (MDA-MB-
231) out of seven breast cancer cell lines investigated. In
contrast, under the same conditions all breast fibroblast lines
consistently exhibited a high capacity for PGE2 production.
Although such arachidonate metabolism is often characteris-
tic ofmammalian fibroblasts derived from various tissues this
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Figure 3 Effect of T-47D breast cancer cells on breast fibroblast-derived PGE2 and recovery of exogenous PGE2. (a) Comparative
effect of PGE2 production in fibroblasts alone and in co-culture with T-47D cells. (b) Comparative effect of fibroblast PGE2
production in T-47D cell-conditioned medium (CM) vs co-culture with T-47D cells. (c) Comparative effect of T-47D and MCF-7
cells (shaded bar) on fibroblast PGE2 production. (d) Comparative effect of T-47D cells and T-47D conditioned medium on
recovery of exogenous PGE2 after 18 h. Inset, recovery of exogenous PGE2 after 1,4 and 22 h incubation in the absence (0) or
presence (0) of T47-D cells. For experimental details on co-culture and CM studies refer to Materials and methods. In (a) , (b)
and (c) cells were incubated without ( ) or with ( ) IL-1Ip (1 ng ml-') for 18 h. The shaded bar in (c) represents co-culture
with MCF-7 cells. Recovery of immunoreactive PGE2 from T47D cell cultures was measured after addition of exogenous PGE2 at
0.5 ng ml-' in (d) and 0.25 ng ml-' in inset. *P<0.01 and **P<0.001 for reduction of basal and IL-lp fibroblast responses by
T-47D or MCF-7 cells in (a), (b) and (c). *P<0.01 for reduced recovery of exogenous PGE2 in the presence of T-47D cells in (d)
and inset.
is to our knowledge the first report of PGE2 production in
human breast stromal cells. Recently an inducible form of
cyclo-oxygenase, COX-2, has been described whose activity
and expression is enhanced by IL-lp and phorbol ester and
inhibited by dexamethasone (Crofford et al., 1994). Despite
possessing receptors for IL-lp (Paciotti and Tamarkin, 1988)
the majority of the cancer cell lines remained unresponsive to
the cytokine, with the exception of Hs578T cells. This cell
line also displayed a potent induction of PGE2 production in
response to the phorbol ester TPA as did MDA-MB-231
cells. The pathophysiological significance of this differential
ability of PGE2 production in breast cancer cell lines is
unknown. Nonetheless, it is perhaps relevant to note that
these hormone-independent cell lines (MDA-MD-231 and
Hs578T) both exhibit an invasive phenotype (Thompson et
al., 1992). It has also been shown that MDA-MA-231 cells
possess an activated c-Ki-ras gene (Kozma et al., 1987) and
Hs578T cells contain an activated H-ras gene (Kraus et al.,
1984). Since ras-transformed cells have been reported to ex-
press elevated cyclo-oxygenase activity and raised basal PGE2
production (Gorman et al., 1991) a possible role for this
proto-oncogene in the regulation of breast cancer cell PGE2
production seems warranted. The apparent disparity between
the high breast tumour tissue PGE2 levels previously reported
and the inability of most human breast cancer cell lines to
synthesise PGE2 remains a paradox. However, this finding is
not exceptional since previous studies have also described
dramatic differences in PGE2 production between cell lines
and primary tumours from specific tissues, including those
derived from human lung, colon, prostate and ovarian
tumours (Hubbard et al., 1988). Again despite the fact that
these tumours are also characterised by elevated PGE2 levels
(Karim and Rao, 1976), the majority of these cell lines with
the exception of certain non-small-cell carcinomas of the
lung, produced little or no detectable PGE2 (Hubbard et al.,
1988; 1989). Nonetheless, it is possible that, despite the high
exogenous arachidonate concentrations used in the present
study, sequestration of substrate via transacylation of phos-
pholipid esters may predominate in some breast cancer cells
and prevent metabolism via cyclo-oxygenase. Alternatively,
rapid metabolic inactivation of any PGE2 formed by the
cancer cells may also limit its detection. Whether the dura-
tion of passage affects the capacity of some cell lines to
synthesise PG is unknown. However, CLF-90-1 cells, from
an early-passage hormone-dependent breast cancer cell line
recently established in our laboratory also fail to synthesise
PGE2. Notwithstanding our present findings, caution must of
course be exercised when interpreting and extrapolating any
such study to tumour cells in vivo.
Interleukin 11B also caused large increases in breast fibro-
blast PGE2 production in the absence and presence of exo-
genous substrate. Hence in addition to cyclo-oxygenase
induction, the cytokine may also increase phospholipase A2
activity as described in other cell types (Lyons-Giordano et
al., 1993). In the absence of added arachidonate, the fibro-
blast PGE2 response to IL-lp was greatly enhanced by BK
and ET-1, both of which are known to stimulate phos-
pholipase A2 in several cell types. Since cyclo-oxygenase
activity in breast fibroblasts appeared to be unaltered by
these peptides, this synergism between peptide and cytokine
may be partly mediated by the concerted activation and
induction of phospholipase A2 and cyclo-oxygenase respec-
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Figure 4 Effect of phorbol ester and cycloheximide on PGE2
metabolism by T-47D breast cancer cells. T-47D cells were
incubated for 24 h with or without TPA (10 nM) or cycloheximide
(CHX; 1 pLM) and the metabolism of [3H]PGE2 (1 gM) was then
monitored during the last 4 h period. Incorporation of radiolabel
into various product bands was then determined following extrac-
tion and TLC (see Materials and methods). (a) Shows typical
radioactivity profiles from single incubations of control (0), TPA
(-) and cycloheximide (A) treated cells. (b) Shows means ± s.d.
values (n = 3) for the sum of the product bands 15-keto PGE2
and PGEM (U) as well as the PGE2 (0) substrate band.
*P<0.02. **P<0.01 for significant changes in relation to basal
values.
tively. Similar synergistic interactions between these
inflammatory mediators have been described previously for
the regulation of PG synthesis in decidual (Schrey et al.,
1992b; Schrey and Hare, 1992), gingival (Lerner and Modeer,
1991) and synovial fibroblasts (Bathon et al., 1989). The
observed inhibition of IL-ip action in breast fibroblasts by
dexamethasone would also be characteristic of and consistent
with a role for COX-2 induction by the cytokine in these
cells as recently described during IL-lp-stimulated PG prod-
uction in other cell types (Crofford et al., 1994).
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The significance of this stromal cell PGE2 production in
response to inflammatory kinins and cytokines with regard to
breast tumour biology is at present uncertain. Nonetheless
IL-lp-mediated increases in matrix-metalloproteinase acti-
vity in the tumour microenvironment may be subject to
negative regulation by PGE2 (Case et al., 1990; Mackay et
al., 1992). We have previously proposed a mediatory auto-
crine role for PGE2 in the inhibition of breast fibroblast
growth by BK (Patel and Schrey, 1992). Interestingly, in this
regard BK has been reported to inhibit the in vivo growth of
spontaneous mammary tumours and sarcomas in mice (Ma-
shiba and Matsunaga, 1985) and SV-40-induced fibrosar-
comas in hamsters (Koppelmann et al., 1978). Stromal PGE2
may also exert an inhibitory paracrine influence on breast
cancer cell growth as evidenced by its anti-proliferative
action on MCF-7 cells (Fentiman et al., 1984).
Notwithstanding an equivocal role for inflammatory medi-
ators such as IL-1p and BK in breast cancer, tumour stroma
generation exhibits many parallels with the processes
involved in inflammation, connective tissue remodelling and
wound repair, including infiltration of cytokine-producing
host immune cells (Whalen, 1990). Furthermore, a number of
studies indicate a local activation of the kallikrien-kinin
cascade in tumours from several different cancers (Maeda et
al., 1988; Karlsrud et al., 1991; Matsumura et al., 1991).
A role for ET-1 as a paracrine mitogen for breast stromal
tissue has been recently implicated (Baley et al., 1990; Schrey
et al., 1992a). This action may partially account for the
extensive desmoplasia seen in breast tumours (Yamashita et
al., 1991, 1992). In the present study we have presented
evidence for a novel potential paracrine cross-talk between
epithelial and stromal breast tumour components involving
ET-1 and PGE2. Thus, ET-1 stimulates PGE2 production by
breast fibroblasts and PGE2 stimulates ET-1 production by
breast cancer cells. Whether such a positive feedback loop
might contribute to the elevated levels of PGE2 and ET-1
seen in breast tumours and to the control of tumour stroma
generation remains speculative.
In an attempt to investigate a potential paracrine control
of breast stromal cell PG production, co-cultures of T-47D
(or MCF-7) cells and breast fibroblasts were employed.
Under these co-culture conditions both basal and IL-lp-
stimulated stromal cell PGE2 production appeared to be
inhibited. Experiments indicating the lack of an inhibitory
effect of T47-D cell-conditioned media on fibroblast PGE2
and a reduced recovery of exogenous PGE2 from T47-D cell
cultures are consistent with metabolic inactivation of PGE2
by the breast cancer cells. This interpretation was further
supported by the metabolic capacity of T47-D cells to readily
convert PGE2 to 15-keto-PGE2. 15-Hydroxy-PG dehydro-
genase, which catalyses this conversion, is considered to be
the key enzyme controlling the biological inactivation of
prostaglandins. Although this enzyme appears to be ubiqui-
tous in mammalian tissues, the specific cell types responsible
for prostaglandin catabolism are uncertain. Clearly, the
regulation of this enzyme may also play an important role in
determining breast tumour tissue PGE2 levels. The produc-
tion of 15-keto-PGE2 in T47-D cells was stimulated by the
phorbol ester TPA and inhibited by cycloheximide treatment.
In accordance with a recent study using the leukaemia HL-60
cell line to investigate 15-hydroxy PG dehydrogenase regula-
tion (Xun et al., 1991) our observations would be consistent
with an induction of the enzyme in T47-D cells by TPA.
Similarily, previous studies have also indicated a loss of
enzyme activity following cycloheximide treatment consistent
with a rapid turnover of the dehydrogenase in lung, kidney
(Blackwell et al., 1975) and HL-60 cells (Xun et al., 1991).
Since maintenance of dehydrogenase activity appears to
require continued de novo enzyme synthesis (Xun et al., 1991)
a susceptibility to hormonal control might be expected. This
is indeed the case with regard to the steroidal regulation of
this PG dehydrogenase in the uterine decidua, where proges-
tins appear to induce the enzyme (Alam et al., 1976) and
anti-progestins are particularly effective in suppressing
enzyme activity and elevating in situ PG concentrations
b -1
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(Cheng et al., 1993). The potential for similar hormonal
regulation of this enzyme in breast tissue requires investiga-
tion. Indeed, PGE2 levels in DMBA-induced rat mammary
tumours increase following ovariectomy (Foecking et al.,
1982) and prostaglandins have also been implicated in mas-
talgia associated with premenstrual syndrome (Budoff, 1986).
Despite the association of elevated PGE2 with a malignant
metastatic phenotype, the value of breast tumour PGE2 levels
as a prognostic indicator remains uncertain. Although initial
studies suggested a poor prognosis in patients with high PG
levels (Bennett et al., 1977) others have shown either no
relationship to established prognostic indices (Wilson et al.,
1980; Watson et al., 1987) or a correlation with favourable
prognostic factors (Karmali et al., 1983; Watson and Chuah,
1985; Fulton et al., 1982). These disparate findings could be
attributed to various factors including: differences in the
techniques employed; substrate availability; and tissue handl-
ing as well as the labile nature of both tissue PGE2 levels per
se and the rapid turnover of the enzymes regulating PGE2
production and metabolism. Interestingly, a recent study
measuring immunoreactive membrane-associated phospho-
lipase A2 in breast tissue reported high expression in malig-
nant vs benign or normal tissue (Yamashita et al., 1993).
Whether this overexpression of phospholipase A2 in malig-
nant breast tissue is instrumental in causing elevated PGE2
levels in these tumours remains to be established.
In summary, this study identifies the breast stromal fibro-
blast as a potential source for PGE2 production in breast
tumours. Putative paracrine factors which may regulate this
arachidonate metabolism include cytokines and peptides such
as IL-1p, kinins and endothelin. We are currently engaged on
a comparative study to determine whether fibroblasts derived
from normal or malignant breast tissue exhibit any
differential capacity for PGE2 synthesis. Since the capacity
for PGE2 production in breast cancer cells appears to be
restricted to oestrogen receptor-negative cell lines with an
invasive phenotype, whether the cancer cells per se contribute
towards prostaglandin synthesis may depend on the specific
histological class of tumour. Finally, metabolic inactivation
by the cancer cells may also play an important regulatory
role in the control of breast tumour PGE2 levels.
Abbreviations
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